Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02102113
Other study ID # 1310012948
Secondary ID
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date January 2014
Est. completion date December 2024

Study information

Verified date May 2024
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria FHP: - Exposure to cannabis at least once in their lifetime - Medically and psychiatrically healthy based on screening - Having one relative with a confirmed psychotic disorder Exclusion Criteria FHP: - Current or lifetime major DSM-IV Axis I disorder - Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness - Major or unstable medical illness that might impact safety of the subject in the study - Cannabis naive - IQ less than 85 - Less than a high school diploma or its educational equivalent - Pregnancy or lactation - Major current or recent (<6 weeks) psychosocial stressors. Inclusion Criteria FHN : - Exposure to cannabis at least once in their lifetime - Medically and psychiatrically healthy based on screening Exclusion Criteria FHN: - Having a family member with psychosis - Current or lifetime major DSM-IV Axis I disorder - Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness - Major or unstable medical illness that might impact safety of the subject in the study - Cannabis naive - IQ less than 85 - Less than a high school diploma or its educational equivalent - Pregnancy or lactation - Major current or recent (<6 weeks) psychosocial stressors.

Study Design


Intervention

Drug:
Placebo
placebo
Very Low Dose THC
Subjects will receive 0.010mg/kg.
Low Dose THC
Subjects will receive 0.018 mg/kg over 20 minutes.

Locations

Country Name City State
United States VA Connecticut Healthcare System West Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive and Negative Symptom Scale for Schizophrenia (PANSS) Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. -30 min from administration of THC
Primary Positive and Negative Symptom Scale for Schizophrenia (PANSS) Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. +80 min from administration of THC
Primary Positive and Negative Symptom Scale for Schizophrenia (PANSS) Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. +150 min of administration of THC
Primary Positive and Negative Symptom Scale for Schizophrenia (PANSS) Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. +240 min of administration of THC
Secondary Clinician Administered Dissociative Symptoms Scale (CADSS) Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment. -30 min, +15 min, +80 min, +150 min, +240 min
Secondary Visual Analog Scale (VAS) Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects. -30 min, +15 min, +80 min, +150 min, +240 min
Secondary Hopkins Verbal Learning Test (HVLT) The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects. +50 min
Secondary Psychotomimetic States Inventory (PSI) The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC. -30 min, +240 min
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A